Kotobuki Pharmaceutical
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Japanese pharmaceutical company focused on manufacturing and developing small molecule drugs in gastroenterology, oncology, and neurology, with expertise in formulation development.
OncologyGastroenterologyNeurologyMetabolic DiseasePain
Technology Platform
Focus on pharmaceutical formulation development, with specialized expertise in creating patient-friendly orally disintegrating (OD) tablets designed for water-free administration.
Opportunities
Growth opportunities include expanding the market for its formulation-advanced products (OD tablets), lifecycle management and geographic expansion (e.g., China) for key assets like gilteritinib, and leveraging its Medical Science Office to build stronger clinical evidence for its portfolio.
Risk Factors
Key risks include reliance on a partnered blockbuster asset (gilteritinib), competition in crowded therapeutic areas like gastroenterology and diabetes, and the challenges of a smaller company in funding broad R&D initiatives against larger pharmaceutical competitors.
Competitive Landscape
Competes with large Japanese pharma (Takeda, Astellas) and global generics/specialty pharma companies in its core areas; differentiation is achieved through specialized formulation technology (OD tablets) and established brand loyalty for products like MARZULENE.